Home Interviews Cereno Scientific discusses phase IIa results for CS1

Cereno Scientific discusses phase IIa results for CS1

Cereno Scientific

Cereno Scientific discusses phase IIa results for CS1

3 October, 2024

The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension.

See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific:

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev